Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating

Related Experiment Video

Updated: Aug 7, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Monika Kasprzycka1, Michal Marzec, Xiaobin Liu

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA.

Proceedings of the National Academy of Sciences of the United States of America
|June 13, 2006
PubMed

Insights

Oncogenic NPM/ALK drives T cell lymphoma by inducing a regulatory T cell (Treg) phenotype. This mechanism involves IL-10 secretion and STAT3 activation, offering new therapeutic targets for ALK+TCL.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The oncogenic nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) tyrosine kinase drives T cell lymphoma (TCL) but its transformation mechanisms are not fully understood.
  • Understanding NPM/ALK's role is crucial for developing targeted therapies against ALK-positive TCL (ALK+TCL).

Purpose of the Study:

  • To elucidate the mechanisms by which NPM/ALK mediates malignant cell transformation in T cell lymphoma.
  • To investigate the role of NPM/ALK in inducing a specific immune cell phenotype within ALK+TCL cells.

Main Methods:

  • Analysis of cytokine secretion (IL-10, TGF-beta) and transcription factor expression (FoxP3) in ALK+TCL cells.
  • Functional assays involving transfection of NPM/ALK into BaF3 cells and inhibition of NPM/ALK activity in ALK+TCL cells.
  • Investigation of signaling pathways, specifically the role of signal transducer and activator of transcription 3 (STAT3).

Main Results:

  • NPM/ALK-carrying ALK+TCL cells exhibit a T regulatory (Treg) cell phenotype, secreting IL-10 and TGF-beta and expressing FoxP3.
  • Secreted IL-10 suppresses normal immune cell proliferation while enhancing ALK+TCL cell viability.
  • The Treg phenotype is dependent on NPM/ALK expression and function, mediated via STAT3 activation.

Conclusions:

  • NPM/ALK oncogenesis involves inducing a Treg phenotype in transformed CD4(+) T cells.
  • Targeting NPM/ALK and/or STAT3 presents a potential therapeutic strategy for ALK+TCL.

More Related Videos

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...